Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More…
Industry, Sector and Symbol
Industry Metal mining
Sub-IndustryN/A
SectorMedical
Phone310-598-5410
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.98 million
Profitability
Miscellaneous
Employees16
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions
What is Opiant Pharmaceuticals' stock symbol?
Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How were Opiant Pharmaceuticals' earnings last quarter?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) released its earnings results on Thursday, August, 8th. The technology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.86. The technology company earned $6.78 million during the quarter, compared to analyst estimates of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. View Opiant Pharmaceuticals' Earnings History.
When is Opiant Pharmaceuticals' next earnings date?
What price target have analysts set for OPNT?
1 Wall Street analysts have issued 12 month target prices for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next year. This suggests a possible upside of 171.1% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.
What is the consensus analysts' recommendation for Opiant Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.
Has Opiant Pharmaceuticals been receiving favorable news coverage?
Media headlines about OPNT stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Opiant Pharmaceuticals.
Are investors shorting Opiant Pharmaceuticals?
Opiant Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 30,800 shares, a decrease of 11.2% from the August 30th total of 34,700 shares. Based on an average trading volume of 19,900 shares, the short-interest ratio is currently 1.5 days. Approximately 0.9% of the company's shares are sold short. View Opiant Pharmaceuticals' Current Options Chain.
Who are some of Opiant Pharmaceuticals' key competitors?
Some companies that are related to Opiant Pharmaceuticals include Mountain Province Diamonds (MPVD), Fission Uranium (FCUUF), Jaguar Mining (JAGGF), Amerigo Resources (ARREF), Rubicon Minerals (RBYCF), Wealth Minerals (WMLLF), Pacific Booker Minerals (PBMLF), Santa Fe Gold (SFEG), Atlatsa Resources (ATLRF), Alderon Iron Ore (AXXDF), Bullfrog Gold (BFGC), Quantum Materials (QTMM), US Gold (USAU), Royal Standard Minerals Inc USA (RYSMF) and Silver Bull Resources (SVBL).
What other stocks do shareholders of Opiant Pharmaceuticals own?
Who are Opiant Pharmaceuticals' key executives?
Opiant Pharmaceuticals' management team includes the folowing people:
- Dr. Roger Crystal, CEO & Director (Age 43)
- Mr. David D. O'Toole, Chief Financial Officer (Age 60)
- Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
- Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
- Mr. Quan Vu, VP of Corp. Devel.
How do I buy shares of Opiant Pharmaceuticals?
Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Opiant Pharmaceuticals' stock price today?
One share of OPNT stock can currently be purchased for approximately $15.49.
How big of a company is Opiant Pharmaceuticals?
Opiant Pharmaceuticals has a market capitalization of $62.60 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.
What is Opiant Pharmaceuticals' official website?
How can I contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]
MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
| Community Ranking: | | 2.4 out of 5 ( ) |
| Outperform Votes: | | 229 (Thanks for Voting!) |
| Underperform Votes: | | 244 (Thanks for Voting!) |
| Total Votes: | | 473 |
